Cargando…

TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche

Myeloproliferative neoplasms (MPNs) are associated with significant alterations in the bone marrow microenvironment that include decreased expression of key niche factors and myelofibrosis. Here, we explored the contribution of TGF-β to these alterations by abrogating TGF-β signaling in bone marrow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Juo-Chin, Oetjen, Karolyn A., Wang, Tianjiao, Xu, Haoliang, Abou-Ezzi, Grazia, Krambs, Joseph R., Uttarwar, Salil, Duncavage, Eric J., Link, Daniel C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151699/ https://www.ncbi.nlm.nih.gov/pubmed/35439167 http://dx.doi.org/10.1172/JCI154092

Ejemplares similares

Canonical signaling by TGF family members in mesenchymal stromal cells is dispensable for hematopoietic niche maintenance under basal and stress conditions
por: Krambs, Joseph Ryan, et al.
Publicado: (2020)

The Hematopoietic Niche in Myeloproliferative Neoplasms
por: Schmitt-Graeff, Annette H., et al.
Publicado: (2015)

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
por: Li, Bing, et al.
Publicado: (2017)

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015)

Bone marrow niche dysregulation in myeloproliferative neoplasms
por: Curto-Garcia, Natalia, et al.
Publicado: (2020)

TGF-β Signaling Plays an Essential Role in the Lineage Specification of Mesenchymal Stem/Progenitor Cells in Fetal Bone Marrow
por: Abou-Ezzi, Grazia, et al.
Publicado: (2019)

Organ Stiffness in the Work-Up of Myelofibrosis and Philadelphia-Negative Chronic Myeloproliferative Neoplasms
por: Benedetti, Edoardo, et al.
Publicado: (2020)

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
por: Talpaz, Moshe, et al.
Publicado: (2020)

Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
por: Yacoub, A., et al.
Publicado: (2014)

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
por: Ianotto, Jean-Christophe, et al.
Publicado: (2018)

Ph-Negative Chronic Myeloproliferative Neoplasm (Primary Myelofibrosis) – as One of the Reasons of the Budd-Chiari Syndrome
por: Sokolova, M., et al.
Publicado: (2012)

Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group
por: Gupta, Vikas, et al.
Publicado: (2020)

Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow
por: Mansour, Anna, et al.
Publicado: (2012)

Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells
por: Lubberich, Richard K., et al.
Publicado: (2018)

Inherited myeloproliferative neoplasm risk impacts hematopoietic stem cells
por: Bao, Erik L., et al.
Publicado: (2020)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms
por: Lim, Sung-Nam, et al.
Publicado: (2013)

A Case of Philadelphia Chromosome Positive Myeloproliferative Neoplasm in a Pregnant Woman with Unusual Primary Myelofibrosis Features
por: Koshy, Jason, et al.
Publicado: (2013)

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Agarwal, M. B., et al.
Publicado: (2015)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence
por: Tefferi, A, et al.
Publicado: (2017)

Predictive Value of miR-146a rs2431697 Polymorphism to Myelofibrosis Progression in Patients with Myeloproliferative Neoplasm
por: Aref, Salah, et al.
Publicado: (2021)

Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes
por: Sochacki, Andrew L, et al.
Publicado: (2016)

Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence
por: Tefferi, A, et al.
Publicado: (2017)

Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives
por: Barosi, Giovanni, et al.
Publicado: (2023)

Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms
por: Tong, Jingyuan, et al.
Publicado: (2021)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
por: Rai, Shivam, et al.
Publicado: (2022)

Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms
por: Mullenders, Jasper, et al.
Publicado: (2015)

Deactylase inhibition in myeloproliferative neoplasms
por: Mithraprabhu, Sridurga, et al.
Publicado: (2010)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

Calreticulin Mutations in Myeloproliferative Neoplasms
por: Lavi, Noa
Publicado: (2014)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Apoptosis deregulation in myeloproliferative neoplasms
por: Tognon, Raquel, et al.
Publicado: (2013)

Mutant Calreticulin in the Myeloproliferative Neoplasms
por: Prins, Daniel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jan3c1cnk8ogriperamsric61i